Eikon Therapeutics, Inc. (EIKN) Stock Statistics & Valuation Metrics

Eikon Therapeutics, Inc. has a market cap or net worth of $520.27M. The enterprise value is $121.99M.

Eikon Therapeutics, Inc. has 54,138,626 shares outstanding. The number of shares has decreased by -2.65% in one year.

Eikon Therapeutics, Inc.’s return on equity (ROE) is 0.37 and return on invested capital (ROIC) is -61.65%.

The current PE Ratio of Eikon Therapeutics, Inc. is ―. Eikon Therapeutics, Inc.’s PEG ratio is 0.00.

In the last 12 months, Eikon Therapeutics, Inc. had revenue of 0.00 and earned -324.25M in profits. Earnings per share was -6.16.

In the last 12 months, operating cash flow was -131.53M and capital expenditures -328.00K, giving a free cash flow of -131.85M billion.

Eikon Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Eikon Therapeutics, Inc. upcoming earnings date is May 11, 2026, Before Open (Confirmed).

Eikon Therapeutics, Inc. as a current ratio of 6.34, with Debt / Equity ratio of 46.28%

In the past 12 months, Eikon Therapeutics, Inc. has paid 0.00 in taxes.

Eikon Therapeutics, Inc. EV to EBITDA ratio is -3.22, with an EV/FCF ratio of -4.10.

Eikon Therapeutics, Inc. has $512.58M in cash and marketable securities with $254.83M in debt, giving a net cash position of $257.75M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Eikon Therapeutics, Inc. is $18.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy